Adult Dosing

Stimulation of pancreatic secretions, including bicarbonate, in the diagnosis of pancreatic exocrine dysfunction

• 0.2 mcg/kg IV over 1 min

Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma

• 0.4 mcg/kg IV over 1 min

Endoscopic retrograde cholangiopancreatography (ERCP)

• 0.2 mcg/kg IV over 1 min

Note:

• Give a test dose of secretin 0.2 mcg (16 mcg/vial) and 0.4 mcg (40 mcg/vial) IV to test for possible allergy before administering secretin

Pediatric Dosing

• Safety and effectiveness in pediatric patients have not been established

[Outline]

• Adult Dosing
• Pediatric Dosing

• Stimulation of pancreatic secretions, including bicarbonate, in the diagnosis of pancreatic exocrine dysfunction
• Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma
• During endoscopic retrograde cholangiopancreatography (ERCP) to facilitate the identification of the ampulla of Vater and accessory papilla [Chirhostim]

• Hypersensitivity to any of the ingredients of the product
• Acute pancreatitis

• N/A

Renal Dose Adjustment

• Renal impairment: Dose adjustments not defined

Hepatic Dose Adjustment

• Hepatic impairment: Use with caution, dose adjustments not defined

• Administer a test dose to identify allergic reaction to secretin, especially in patients with a history of atopic allergy and/or asthma. If no allergic reaction is noted after 1 min, administer the recommended dose
• Results of secretin stimulation tests should be interpreted with caution in patients who have undergone vagotomy or who have inflammatory bowel disease, as they respond less to secretin stimulation and may give false positive result of pancreatic diseases
• Patients with alcoholic or other liver disease may present a greater-than-normal volume response to secretin stimulation and may mask the coexisting pancreatic diseases. Thus the results of secretin stimulation tests should be interpreted with caution in these patients

Cautions: Use cautiously in

• Liver diseases
• Inflammatory bowel diseases
• Vagotomy
• Concomitant anticholinergic agents

Pregnancy Category:C

Breastfeeding: Safety unknown, as many drugs are excreted in human milk manufacturer advises caution while administering to nursing woman.

• CV: Bradycardia, hypotension, tachycardia
• NEURO: Tingling in legs
• CNS: Anxiety, faintness, sedation
• GI: Nausea, abdominal pain, abdominal discomfort, bleeding-sphincterectomy, bloating, diarrhea, increase oral secretions, burning in stomach, warm sensation in abdomen
• RESP: Transient respiratory distress
• DERM: Diaphoresis, urticaria, clammy skin
• MISC: Fever, decreased O2 saturation, warm sensation in face

• Diagnostic Agent; binds to the secretin receptor found on the lining of S cells in the duodenum and G cells in the stomach leading to the secretion of bicarbonate from bicarbonate producing organs or reduction of the secretion of gastrin
• Metabolism: Unknown
• Excretion: After 0.4 mcg/kg IV administration, plasma concentration rapidly declines to baseline secretin levels within 90 to 120 min
• Half life
• Chirhostim: 45 mins
• SecreFlo: 27 mins

US Trade Name(s)

• SecreFlo
• Chirhostim

US Availability

SecreFlo

• PWDR for INJ: 16 mcg/vial

Chirhostim

• PWDR for INJ: 16 mcg/vial

Canadian Trade Name(s)

• N/A

Canadian Availability

• N/A

UK Trade Name(s)

• N/A

UK Availability

• N/A

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Endocrine/Metabolic

Diagnostic Agents

Gastrointestinal

Diagnostic Agents